Home > Research > Publications & Outputs > Cognitive functioning and GABAA/benzodiazepine ...
View graph of relations

Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study. / Ball, Suzanne; Busatto, Geraldo F.; David, Anthony S. et al.
In: Biological Psychiatry, Vol. 43, No. 2, 01.1998, p. 107-117.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Ball, S, Busatto, GF, David, AS, Jones, SH, Hemsley, DR, Pilowsky, LS, Costa, DC, Ell, PJ & Kerwin, RW 1998, 'Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study.', Biological Psychiatry, vol. 43, no. 2, pp. 107-117. https://doi.org/10.1016/S0006-3223(97)00300-4

APA

Ball, S., Busatto, G. F., David, A. S., Jones, S. H., Hemsley, D. R., Pilowsky, L. S., Costa, D. C., Ell, P. J., & Kerwin, R. W. (1998). Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study. Biological Psychiatry, 43(2), 107-117. https://doi.org/10.1016/S0006-3223(97)00300-4

Vancouver

Ball S, Busatto GF, David AS, Jones SH, Hemsley DR, Pilowsky LS et al. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study. Biological Psychiatry. 1998 Jan;43(2):107-117. doi: 10.1016/S0006-3223(97)00300-4

Author

Ball, Suzanne ; Busatto, Geraldo F. ; David, Anthony S. et al. / Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study. In: Biological Psychiatry. 1998 ; Vol. 43, No. 2. pp. 107-117.

Bibtex

@article{00577f7b2d374169affd38aff0c9e950,
title = "Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study.",
abstract = "Background: The role of the inhibitory neurotransmitter gamma aminobutyric acid (GABA) in schizophrenia has previously been investigated using postmortem material. Recently, using single photon emission tomography (SPET) with the selective benzodiazepine antagonist 123I-lomazenil as the radioligand, we have demonstrated an in vivo relationship between reduced GABAA/benzodiazepine receptor binding and the severity of positive symptomatology in schizophrenia. The present study aimed to build on this using the same in vivo scanning techniques, and relating findings to cognitive functioning. Methods: Ten nonpsychiatric control subjects and 15 schizophrenic patients, matched for age and handedness, were scanned. A battery of neuropsychologic tests was also administered. Results: Correlational analysis revealed a pattern of increased correlations between GABAA/benzodiazepine receptor binding and task performance, in the schizophrenic group compared to the control group. Conclusions: Findings are preliminary but suggest a relationship between reduced GABAA/benzodiazepine receptor binding and poorer cognitive functioning, involving memory and visual attention processes, in the schizophrenic group but not in the control group. A role for GABA in the pathophysiology of schizophrenia is suggested. Limitations of the present study and suggestions for future research are discussed.",
keywords = "GABA, schizophrenia, neuropsychology, SPET, lomazenil, benzodiazepine receptor",
author = "Suzanne Ball and Busatto, {Geraldo F.} and David, {Anthony S.} and Jones, {Steven H.} and Hemsley, {David R.} and Pilowsky, {Lynn S.} and Costa, {Durval C.} and Ell, {Peter J.} and Kerwin, {Robert W.}",
year = "1998",
month = jan,
doi = "10.1016/S0006-3223(97)00300-4",
language = "English",
volume = "43",
pages = "107--117",
journal = "Biological Psychiatry",
issn = "1873-2402",
publisher = "Elsevier USA",
number = "2",

}

RIS

TY - JOUR

T1 - Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study.

AU - Ball, Suzanne

AU - Busatto, Geraldo F.

AU - David, Anthony S.

AU - Jones, Steven H.

AU - Hemsley, David R.

AU - Pilowsky, Lynn S.

AU - Costa, Durval C.

AU - Ell, Peter J.

AU - Kerwin, Robert W.

PY - 1998/1

Y1 - 1998/1

N2 - Background: The role of the inhibitory neurotransmitter gamma aminobutyric acid (GABA) in schizophrenia has previously been investigated using postmortem material. Recently, using single photon emission tomography (SPET) with the selective benzodiazepine antagonist 123I-lomazenil as the radioligand, we have demonstrated an in vivo relationship between reduced GABAA/benzodiazepine receptor binding and the severity of positive symptomatology in schizophrenia. The present study aimed to build on this using the same in vivo scanning techniques, and relating findings to cognitive functioning. Methods: Ten nonpsychiatric control subjects and 15 schizophrenic patients, matched for age and handedness, were scanned. A battery of neuropsychologic tests was also administered. Results: Correlational analysis revealed a pattern of increased correlations between GABAA/benzodiazepine receptor binding and task performance, in the schizophrenic group compared to the control group. Conclusions: Findings are preliminary but suggest a relationship between reduced GABAA/benzodiazepine receptor binding and poorer cognitive functioning, involving memory and visual attention processes, in the schizophrenic group but not in the control group. A role for GABA in the pathophysiology of schizophrenia is suggested. Limitations of the present study and suggestions for future research are discussed.

AB - Background: The role of the inhibitory neurotransmitter gamma aminobutyric acid (GABA) in schizophrenia has previously been investigated using postmortem material. Recently, using single photon emission tomography (SPET) with the selective benzodiazepine antagonist 123I-lomazenil as the radioligand, we have demonstrated an in vivo relationship between reduced GABAA/benzodiazepine receptor binding and the severity of positive symptomatology in schizophrenia. The present study aimed to build on this using the same in vivo scanning techniques, and relating findings to cognitive functioning. Methods: Ten nonpsychiatric control subjects and 15 schizophrenic patients, matched for age and handedness, were scanned. A battery of neuropsychologic tests was also administered. Results: Correlational analysis revealed a pattern of increased correlations between GABAA/benzodiazepine receptor binding and task performance, in the schizophrenic group compared to the control group. Conclusions: Findings are preliminary but suggest a relationship between reduced GABAA/benzodiazepine receptor binding and poorer cognitive functioning, involving memory and visual attention processes, in the schizophrenic group but not in the control group. A role for GABA in the pathophysiology of schizophrenia is suggested. Limitations of the present study and suggestions for future research are discussed.

KW - GABA

KW - schizophrenia

KW - neuropsychology

KW - SPET

KW - lomazenil

KW - benzodiazepine receptor

U2 - 10.1016/S0006-3223(97)00300-4

DO - 10.1016/S0006-3223(97)00300-4

M3 - Journal article

VL - 43

SP - 107

EP - 117

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 1873-2402

IS - 2

ER -